MS Clinical Trial starting at East Kent

Rex Bionics is the pioneer of the REX® robotic rehabilitation device that provides standing, walking and exercise support for people with lower limb weakness or paralysis; and is used by people who have suffered a spinal cord injury, stroke, traumatic brain injury or other neurological condition such as multiple sclerosis.

Rex Bionics has worked with physiotherapists to develop the practice of Robot-Assisted Physiotherapy, also known as REXERCISES. In a REXERCISE session, REX lifts patients from a sitting position into a robot-supported standing position, allowing them to take part in a set of supported walking and stretching exercises and core and upper body strengthening and conditioning exercises, designed by specialist physiotherapists.

Rex Bionics is pleased to announce the commencement of the RAPPER IV Clinical trial at East Kent Hospitals University. RAPPER IV is a feasibility trial designed to evaluate a balance rehabilitation program enabled by REX in patients with Multiple Sclerosis. This trial follows on from the successful RAPPER III trial.

Participants, partners and spouses will also be invited to take part in a qualitative study to gain further insight into their experience of using the REX in neuro-rehabilitation.

The trial will take place at Kent & Canterbury Hospital over a period of 7 weekends from February 2019 onwards.

The trial is being led by Dr Mohamed Sakel FRCP (UK) Chief Investigator, Director and Consultant Physician in Neuro-rehabilitation. Dr Sakel says “I am excited to be following up on the promising work done previously to see how a robotic exoskeleton can help in rehabilitation for people with MS.”. Dr Sakel acknowledges the moral support and encouragement received from the local charity MS Therapy Centre of Canterbury, UK.

Rex Bionics Chief Executive, Dr Charles Carignan says “REX offers assistance to a wide range of patients in rehabilitation clinics and we are very happy to be working once again with Dr Sakel’s team at East Kent and his MS patients.”

For further details on the study please contact Dr Mohamed Sakel msakel@nhs.net.

For more information on Rex Bionics please contact Tracey White, General Manager tracey.white@rexbionics.com